TETRAPHASE PHARMACEUTICALS INC Accounts Receivable
TETRAPHASE PHARMACEUTICALS INC had Accounts Receivable of $1.71 million as of 2020-03-31, per its 10-Q filed 2020-05-07.
Discontinued › Balance Sheet › Assets › Assets, Current
us-gaap:AccountsReceivableNetCurrent · last filed 2020-05-07
- 2020-03-31: Accounts Receivable, after Allowance for Credit Loss, Current $1.71M.
- 2019-12-31: Accounts Receivable, after Allowance for Credit Loss, Current $1.50M.
- 2019-09-30: Accounts Receivable, after Allowance for Credit Loss, Current $1.71M.
- 2019-06-30: Accounts Receivable, after Allowance for Credit Loss, Current $1.73M.
| Period end | Accounts Receivable, after Allowance for Credit Loss, Current |
|---|---|
| 2020-03-31 | $1.71M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $1.50M 10-Q · filed 2020-05-07 |
| 2019-09-30 | $1.71M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $1.73M 10-Q · filed 2019-08-08 |
| 2019-03-31 | $1.82M 10-Q · filed 2019-05-08 |
| 2018-12-31 | $2.27M 10-K · filed 2020-03-12 |
| 2018-09-30 | $2.60M 10-Q · filed 2018-11-09 |
| 2018-06-30 | $3.11M 10-Q · filed 2018-08-02 |
| 2018-03-31 | $3.21M 10-Q · filed 2018-05-03 |
| 2017-12-31 | $4.65M 10-K · filed 2019-03-15 |
| 2017-09-30 | $3.56M 10-Q · filed 2017-11-01 |
| 2017-06-30 | $2.68M 10-Q · filed 2017-08-02 |
| 2017-03-31 | $1.70M 10-Q · filed 2017-05-08 |
| 2016-12-31 | $1.79M 10-K · filed 2018-03-06 |
| 2016-09-30 | $745.00K 10-Q · filed 2016-11-03 |
| 2016-06-30 | $2.98M 10-Q · filed 2016-08-04 |
| 2016-03-31 | $3.84M 10-Q · filed 2016-05-04 |
| 2015-12-31 | $4.15M 10-K · filed 2017-03-13 |
| 2015-09-30 | $3.07M 10-Q · filed 2015-11-02 |
| 2015-06-30 | $3.42M 10-Q · filed 2015-08-06 |
| 2015-03-31 | $5.48M 10-Q · filed 2015-05-07 |
| 2014-12-31 | $3.46M 10-K · filed 2016-02-25 |
| 2014-09-30 | $1.95M 10-Q · filed 2014-11-10 |
| 2014-06-30 | $1.34M 10-Q · filed 2014-08-12 |
| 2014-03-31 | $2.02M 10-Q · filed 2014-05-12 |
| 2013-12-31 | $1.71M 10-K · filed 2015-03-06 |
| 2013-09-30 | $2.13M 10-Q · filed 2013-11-14 |
| 2013-06-30 | $2.91M 10-Q · filed 2013-08-12 |
| 2013-03-31 | $1.91M 10-Q · filed 2013-05-13 |
| 2012-12-31 | $2.45M 10-K · filed 2014-03-06 |